In breast cancer, paclitaxel resistance occurs due to circHIPK3/miR-1286/HK2 modulation and consequent cell cycle progression and apoptosis inhibition (14); and trastuzumab resistance occurs through the transmission of circHIPK3 via exosomes and miR-582-3p/RNF11 axis regulation, which promotes cell proliferation, invasion, and apoptosis inhibition (16). Here, HK2 is linked to breast cancer.